All In Biotech

NDA 208261 · Msd Sub Merck

Zepatier

Elbasvir, Grazoprevir · Oral · Hepatitis C Virus NS5A Inhibitor; Hepatitis C Virus NS3/4A Protease Inhibitor

NovelBreakthrough therapyPriority reviewDiscontinued

Last checked: Nov 19, 2026Latest source record: Dec 9, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2016

Jan 28, 2016

Approved uses

2

Original approval plus efficacy supplements

Registered trials

69

22 Phase 3, 0 recruiting

FAERS reports

4,249

1,435 serious, 123 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with ZEPATIER. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ]. WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B...

What it is approved for

From the label in effect Mar 13, 2026.

ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration (2.2) ] . ZEPATIER is a fixed-dose combination product containing elbasvir, a hepatitis C virus (HCV) NS5A inhibitor, and grazoprevir, an HCV NS3/4A protease inhibitor, and is indicated for treatment of chronic HCV genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations. ( 1 )

Mechanism: ZEPATIER is a fixed-dose combination of elbasvir and grazoprevir which are direct-acting antiviral agents against the hepatitis C virus [see Microbiology (12.4) ].

Therapeutic areas: Infectious disease and vaccines

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 9, 2021 Supplement 7 · Efficacy LabelLetter
  • Jan 28, 2016 Original approval · Type 1 - New Molecular Entity and Type 4 - New Combination · priority review NovelBreakthrough therapyReviewSummary ReviewLetter
1 products under this application
  • ZEPATIER · ELBASVIR 50MG; GRAZOPREVIR 100MG · TABLET, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Elbasvir" as an intervention, any sponsor and status, largest first.

All 69 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue958
  • headache756
  • nausea558
  • insomnia313
  • diarrhoea256
  • drug dose omission253
  • vomiting182
  • adverse event150
  • pneumonia147
  • hepatitis c137
  • arthralgia133
  • pruritus123

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20152
2016656
20172,382
2018684
2019242
202079
202139
202230
202314
202469
202545
20267

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Zepatier (Elbasvir/Grazoprevir)

2024 spending

$224K

Beneficiaries

14

32 claims

Per beneficiary

$15,975

$249.61 per unit

View as table
YearSpending
2020$1,126,256
2021$616,424
2022$343,063
2023$467,651
2024$223,652

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 63 on PubMed

Sponsor: Merck & Co.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.